A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Exclusion Criteria

• •Measurable disease per RECIST v1.1.
• •Eastern Cooperative Oncology Group performance status 0 to 1.
• •Willingness to avoid pregnancy or fathering children.
• •Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug.
• •Prior treatment with PD-1 or PD-L1 directed therapy (other immunotherapies may be acceptable with prior approval from the medical monitor).
• •Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy; 6 months for thoracic region radiotherapy that is \> 30 Gy.
• •Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of anemia not requiring transfusion support and any grade of alopecia). Endocrinopathy, if well-managed, is not exclusionary and should be discussed with sponsor medical monitor.
• •Has not recovered adequately from toxicities and/or complications from surgical intervention before starting study drug.
• •Laboratory values outside the protocol-defined range at screening.
• •Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 3 years of study entry.
• +10 more criteria